These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 8599487

  • 41. [Impossible treatment of gonorrhea].
    Barfod S.
    Ugeskr Laeger; 2000 Aug 21; 162(34):4557. PubMed ID: 10981227
    [No Abstract] [Full Text] [Related]

  • 42. Cefixime in the treatment of uncomplicated gonorrhea.
    Dunnett DM, Moyer MA.
    Sex Transm Dis; 1992 Aug 21; 19(2):92-3. PubMed ID: 1595018
    [Abstract] [Full Text] [Related]

  • 43. Dose-ranging study of ceftriaxone for uncomplicated gonorrhea in men.
    Handsfield HH, Murphy VL, Holmes KK.
    Antimicrob Agents Chemother; 1981 Dec 21; 20(6):839-40. PubMed ID: 6275788
    [Abstract] [Full Text] [Related]

  • 44. [Cefixime therapy in patients with proven gonorrhea].
    Backhaus A, Tinzl J.
    Infection; 1990 Dec 21; 18 Suppl 3():S145-6. PubMed ID: 2079375
    [Abstract] [Full Text] [Related]

  • 45. Comparison of enoxacin and ceftriaxone in the treatment of uncomplicated gonorrhea.
    Covino JM, Smith BL, Cummings MC, Benes S, Draft K, McCormack WM.
    Sex Transm Dis; 1993 Dec 21; 20(4):227-9. PubMed ID: 8211540
    [Abstract] [Full Text] [Related]

  • 46. Should women be tested for gonococcal infection of the cervix during routine gynecologic visits? An economic appraisal.
    Phillips RS, Safran C, Aronson MD, Taylor WC.
    Am J Med; 1989 Mar 21; 86(3):297-302. PubMed ID: 2493192
    [Abstract] [Full Text] [Related]

  • 47. Potential deleterious effects of promoting the use of ceftriaxone in the treatment of Neisseria gonorrhoeae.
    Golden MR, Barbee LA, Kerani R, Dombrowski JC.
    Sex Transm Dis; 2014 Oct 21; 41(10):619-25. PubMed ID: 25211259
    [Abstract] [Full Text] [Related]

  • 48. Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011.
    Ison CA, Town K, Obi C, Chisholm S, Hughes G, Livermore DM, Lowndes CM, GRASP collaborative group.
    Lancet Infect Dis; 2013 Sep 21; 13(9):762-8. PubMed ID: 23764300
    [Abstract] [Full Text] [Related]

  • 49. Evaluating the cost-effectiveness of treatment with third-generation cephalosporins.
    Gladen HE.
    Diagn Microbiol Infect Dis; 1992 Jan 21; 15(1):99-105. PubMed ID: 1730191
    [Abstract] [Full Text] [Related]

  • 50. Cefotetan therapy for gonococcal urethritis and cervicitis.
    Youssef RZ, Murray M, Holmes B, Mogabgab WJ.
    Sex Transm Dis; 1990 Jan 21; 17(2):99-101. PubMed ID: 2360135
    [Abstract] [Full Text] [Related]

  • 51. Cost-Effectiveness of Dual Antimicrobial Therapy for Gonococcal Infections Among Men Who Have Sex With Men in the Netherlands.
    Xiridou M, Lugnér A, de Vries HJ, van Bergen JE, Götz HM, van Benthem BH, Wallinga J, van der Sande MA.
    Sex Transm Dis; 2016 Sep 21; 43(9):542-8. PubMed ID: 27513379
    [Abstract] [Full Text] [Related]

  • 52. Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials.
    Bai ZG, Bao XJ, Cheng WD, Yang KH, Li YP.
    Int J STD AIDS; 2012 Feb 21; 23(2):126-32. PubMed ID: 22422688
    [Abstract] [Full Text] [Related]

  • 53. Cost-effectiveness analysis of five different antibiotic regimens for the treatment of uncomplicated Chlamydia trachomatis cervicitis.
    Nuovo J, Melnikow J, Paliescheskey M, King J, Mowers R.
    J Am Board Fam Pract; 1995 Feb 21; 8(1):7-16. PubMed ID: 7701965
    [Abstract] [Full Text] [Related]

  • 54. Comparative study of ceftriaxone and spectinomycin in the treatment of uncomplicated gonorrhea in women.
    Collier AC, Judson FN, Murphy VL, Leach LA, Root CJ, Handsfield HH.
    Am J Med; 1984 Oct 19; 77(4C):68-72. PubMed ID: 6093523
    [Abstract] [Full Text] [Related]

  • 55. Gonorrhea Treatment Failures With Oral and Injectable Expanded Spectrum Cephalosporin Monotherapy vs Dual Therapy at 4 Canadian Sexually Transmitted Infection Clinics, 2010-2013.
    Singh AE, Gratrix J, Martin I, Friedman DS, Hoang L, Lester R, Metz G, Ogilvie G, Read R, Wong T.
    Sex Transm Dis; 2015 Jun 19; 42(6):331-6. PubMed ID: 25970311
    [Abstract] [Full Text] [Related]

  • 56. Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae.
    Muratani T, Inatomi H, Ando Y, Kawai S, Akasaka S, Matsumoto T.
    Int J Urol; 2008 Sep 19; 15(9):837-42. PubMed ID: 18665871
    [Abstract] [Full Text] [Related]

  • 57. [Non-viral sexually transmitted infections - Epidemiology, clinical manifestations, diagnostics and therapy : Part 1: Gonococci].
    Nenoff P, Manos A, Ehrhard I, Krüger C, Paasch U, Helmbold P, Handrick W.
    Hautarzt; 2017 Jan 19; 68(1):43-49. PubMed ID: 27981386
    [Abstract] [Full Text] [Related]

  • 58. Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men.
    Megran DW, Lefebvre K, Willetts V, Bowie WR.
    Antimicrob Agents Chemother; 1990 Feb 19; 34(2):355-7. PubMed ID: 2183719
    [Abstract] [Full Text] [Related]

  • 59. Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime.
    Hitt CM, Nightingale CH, Quintiliani R, Nicolau DP.
    Am J Health Syst Pharm; 1997 Jul 15; 54(14):1614-8. PubMed ID: 9248605
    [Abstract] [Full Text] [Related]

  • 60. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae--Hawaii and California, 2001.
    Centers for Disease Control and Prevention (CDC).
    MMWR Morb Mortal Wkly Rep; 2002 Nov 22; 51(46):1041-4. PubMed ID: 12487525
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.